Reference health
Development and Validation of Nomograms to Predict Outcome Following LuPSMA Radionuclide Treatment for Metastatic Castration-Resistant Prostate Cancer: A Multicenter International Study
20/20 checkable references clean · checked 2026-08-29
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
10 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 20 checked references that resolve
resolves10.1186/s13045-020-00978-z
Novel therapies are changing treatment paradigms in metastatic prostate cancer
resolves10.1016/s1470-2045(18)30198-0
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
resolves10.1016/j.clgc.2018.09.014
Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression
resolves10.1016/S0140-6736(20)30314-7
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
resolves10.1200/jco.2013.52.3696
Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer
resolves10.1200/jco.2013.50.3201
Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy
resolves10.1186/1755-8794-4-31
Optimally splitting cases for training and testing high dimensional classifiers
resolves10.1200/JCO.2015.64.2702
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
resolves10.2967/jnumed.117.198119
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
resolves10.1016/j.eururo.2020.05.004
Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study
resolves10.18632/oncotarget.21600
Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy
resolves10.2967/jnumed.119.240242
Early Prostate-Specific Antigen Changes and Clinical Outcome After <sup>177</sup>Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer
resolves10.1016/j.jbi.2008.08.010
Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support
resolves10.1200/jco.2019.37.15_suppl.5028
RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer.
resolves10.1007/s00259-020-04723-z
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
resolves10.1093/jnci/djt280
Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy
resolves10.1055/s-0039-1683592
Resistance against PSMA-targeting alpha-radiation therapy coincides with mutations in DNA-repair associated genes
The 10 references without a DOI — listed, not checked
no DOI — not checkedMulticenter Study Investigating 177Lu-375 PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
no DOI — not checkedRadioligand Therapy with (177)Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer
no DOI — not checkedref6
no DOI — not checkedref8
no DOI — not checkedref12
no DOI — not checkedTheraP: a randomized phase 2 trial of (177) Lu-PSMA-617 431 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer 432 (Clinical Trial Protocol ANZUP 1603)
no DOI — not checkedRadiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes
no DOI — not checkedref28
no DOI — not checkedAmerican Joint Committee on Cancer acceptance criteria for 444 inclusion of risk models for individualized prognosis in the practice of precision medicine
no DOI — not checkedref30
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-08-29 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.2139/ssrn.3798566"><img src="https://citestamp.com/citestamped/10.2139/ssrn.3798566/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.2139/ssrn.3798566)